Immunotherapy and CRISPR cas systems: potential cure of COVID-19?
X He, XX Zeng - Drug Design, Development and Therapy, 2023 - Taylor & Francis
The COVID-19 has plunged the world into a pandemic that affected millions. The continually
emerging new variants of concern raise the question as to whether the existing vaccines will …
emerging new variants of concern raise the question as to whether the existing vaccines will …
[HTML][HTML] Global Dynamics of SARS-CoV-2 Infection with Antibody Response and the Impact of Impulsive Drug Therapy
Mathematical modeling is crucial to investigating tthe ongoing coronavirus disease 2019
(COVID-19) pandemic. The primary target area of the SARS-CoV-2 virus is epithelial cells in …
(COVID-19) pandemic. The primary target area of the SARS-CoV-2 virus is epithelial cells in …
AMMI Canada Practice Point on the treatment of acute COVID-19 in pediatrics
J Autmizguine, M Barton, C Burton… - Official Journal of …, 2022 - jammi.utpjournals.press
Julie Autmizguine MD, MSc1, 2, Michelle Barton MD, MSc3, Catherine Burton MD, MSc4,
Devika Dixit MD, MSc, DTMH, CTropMed5, Jesse Papenburg MD, MSc6, 7, Joan Robinson …
Devika Dixit MD, MSc, DTMH, CTropMed5, Jesse Papenburg MD, MSc6, 7, Joan Robinson …
[PDF][PDF] Global Dynamics of SARS-CoV-2 Infection with Antibody Response and the Impact of Impulsive Drug Therapy. Vaccines 2022, 10, 1846
Mathematical modeling is crucial to investigating tthe ongoing coronavirus disease 2019
(COVID-19) pandemic. The primary target area of the SARS-CoV-2 virus is epithelial cells in …
(COVID-19) pandemic. The primary target area of the SARS-CoV-2 virus is epithelial cells in …
Evaluating the future of monoclonal antibody therapy for SARS-CoV-2
J Setiawan - Undergraduate Journal of Experimental Microbiology …, 2022 - ojs.library.ubc.ca
A range of therapeutic options exist for those at high risk for developing severe coronavirus
disease 2019 (COVID-19) infection. Monoclonal antibody (mAb) therapies and antiviral …
disease 2019 (COVID-19) infection. Monoclonal antibody (mAb) therapies and antiviral …
[PDF][PDF] Terapia de REGEN COV como base de terapia inmunomoduladora mixta en pacientes hospitalizados por neumonía por SARS-CoV-2: Serie de casos
Introducción: los países en desarrollo con sistema de salud de baja inversión encuentran un
reto en priorizar el tratamiento de COVID-19 según su eficacia y sus costos. Materiales y …
reto en priorizar el tratamiento de COVID-19 según su eficacia y sus costos. Materiales y …